Complimentary Webinar: Pharmacy Strategies to Limit Business Disruption from Suspicious Order Monitoring
May 14 @ 12:15 pm - 1:00 pm
The Drug Enforcement Administration, itself under fire for failing to effectively curb the Nation’s opioid epidemic, has increased pressure on industry, and wholesalers in particular, to limit the distribution of controlled substances. Pending DEA rules further seek to involve distributors in the investigation and reporting of their pharmacy clients by requiring “due diligence” in the filling of orders for controlled substances. The lack of clear uniform standards regarding the reporting of suspicious orders and due diligence investigations means that standards and criteria will be inconsistent from one wholesaler to the next, thereby increasing pharmacy burden, lack of transparency and business disruption. Pharmacies need to develop strategies to mitigate these adverse consequences.
Join us on May 14, 2021 at 12:15 p.m. for an understanding of DEA rules regarding upstream supply chain reporting obligations, evolving suspicious order reporting and investigative requirements, and techniques designed to limit the degree of interruptions to your business as a result.
Our presenter, Anthony Mahajan, Esq., previously served as Chief Counsel to McKesson Corp., where he was responsible for providing legal advice to the business regarding compliance with suspicious order reporting requirements and McKesson’s 2017 settlement with the Department of Justice and DEA regarding controlled substances. He also formerly worked as an Assistant United States Attorney in the District of New Jersey, where he investigated and prosecuted numerous controlled substance offenses against manufacturers, distributors, pharmacies and health care professionals. Mr. Mahajan currently serves as Chair of Frier Levitt’s White Collar Defense & Government Investigations practice.